DexCom, Inc. (DXCM)
Nasdaq · San Diego, California, USA · Founded 1999 · CEO Jake Leach
Valuation summary
$34.11 fair value versus $80.19 in the market, a difference of -57.5%. Rated Sell.
| Fair value per share | $34.11 |
| Current share price | $80.19 |
| Upside / downside | -57.5% |
| Bear case | $21.74 |
| Bull case | $51.87 |
| Discount rate (WACC) | 10.4% |
| Terminal growth | 3.00% |
| Market capitalisation | $30B |
| EV / Sales | 6.1x |
About DexCom, Inc.
Founded in 1999. Jake Leach is president and chief executive. DexCom makes continuous glucose monitors — small sensors worn on the body that track blood sugar in real time and send it to a phone, replacing finger-prick testing. The market is expanding well beyond insulin-dependent diabetics into type 2 patients and general metabolic health monitoring.
Investment case
- Continuous glucose monitoring is still substantially under-penetrated even among insulin users.
- Expansion into type 2 diabetes multiplies the addressable population.
- The consumables model produces highly recurring revenue per patient.
Key risks
- Abbott's Libre competes directly and is priced more aggressively.
- Reimbursement decisions by insurers determine how fast the market can expand.
- A US sales force reorganisation caused a growth stumble that damaged credibility.
Recent developments
- 2026-10-29 · Q3 revenue of $1.344bn and EPS of $0.72 beat estimates as margins hit a multi-year high; full-year guidance raised source
- 2026-10-07 · DexCom will report third-quarter 2026 results after the market closes on 29 October 2026. source
- 2026-09-28 · DexCom published a Type 2 diabetes survey report at EASD 2026 and a monitoring partnership with Team Novo Nordisk. source
- 2026-09-14 · CFO Jereme Sylvain was also named chief operating officer; the release names Jake Leach as president and CEO. source
Revenue by segment
| US Sensor & Hardware | 70% |
| International | 30% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $5.6B | $0.6B |
| Year 2 | $6.3B | $0.7B |
| Year 3 | $7.0B | $0.8B |
| Year 4 | $7.7B | $0.9B |
| Year 5 | $8.4B | $1.0B |
What the street says
The category growth is not in doubt; DexCom's share of it against Abbott is.
Comparable companies: RMD · IDXX · GEHC · MDLN · BSX · IQV · A · CAH
Open the interactive model, price chart and sensitivity grid →